Text
Xervyteg® marks a major advance in microbiome therapeutics, with potential to become the first approved microbiota therapy in Europe.
Fungal metabolites such as FF-C1 may offer a new therapeutic approach for treating MAFLD and related conditions.
Certain barriers on the skin prevent easy colonization of new strains and specific life stages, such as adolescence, may be crucial for successful probiotic interventions.
World Microbiome Day: celebrating the invisible allies transforming health, business, and the planet
With the theme “Microbiome 101: What You Need to Know”, this year's WMD makes a bold and timely move: bringing microbiome science back to basics, and straight into the hands…
Danone has announced the acquisition of The Akkermansia Company (TAC), significantly expanding its investment into gut health and next-generation biotic research.
Even small differences between strains of gut bacteria—often within the same species—can sway how these microbes interact with the human body and influence disease outcomes.
A microbiota-mediated macrophage-dependent mechanism may be used to reduce diabetes incidence in vivo.
Industry
Sponsored by
An interview to SynBalance Marketing Manager, Silva Castegnaro on the latest clinically backed solutions shaping the future of biotics world.
Genetic factors can influence tumor-associated microbes, offering insights into colorectal cancer progression and potential therapeutic targets.
TCA can help to manage IBD by supporting the gut barrier and influencing microbiota composition.
